Byooviz

Full Title

These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar to LUCENTIS (ranibizumab injection) - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of BYOOVIZ has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.